Catalyst
Slingshot members are tracking this event:
Spruce Biosciences (SPRB) to announce Phase 1 and 2 Data of Tildacerfont in Classic Congenital Adrenal Hyperplasia at ENDO March 20, 2021 at 11:00am EST
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SPRB | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 20, 2021
Occurred Source:
https://www.abstractsonline.com/pp8/#!/9188/presentation/2259
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Congenital Adrenal Hyperplasia, Tildacerfont
